Online inquiry

IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12806MR)

This product GTTS-WQ12806MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MASP2 gene. The antibody can be applied in Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_006610.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10747
UniProt ID O00187
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12806MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ346MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ12912MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ12701MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ10530MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ9990MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ556MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ5012MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ1490MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW